Larkin JMG, et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma. Abstract LBA68_PR. ESMO Congress 2019, 28 sept, Barcelona, Spanje.
Management van T-DXd-geassocieerde ILD bij HER2-positieve gemetastaseerde borstkanker
sep 2023 | Borstkanker, ILD